Insight Molecular Diagnostics (IMDX) Common Equity (2016 - 2026)
Insight Molecular Diagnostics' Common Equity history spans 7 years, with the latest figure at -$31.5 million for Q4 2025.
- On a quarterly basis, Common Equity fell 156.35% to -$31.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$31.5 million, a 156.35% decrease, with the full-year FY2025 number at -$31.5 million, down 156.35% from a year prior.
- Common Equity hit -$31.5 million in Q4 2025 for Insight Molecular Diagnostics, down from -$9.2 million in the prior quarter.
- Over the last five years, Common Equity for IMDX hit a ceiling of $106.6 million in Q1 2021 and a floor of -$31.5 million in Q4 2025.
- Historically, Common Equity has averaged $38.3 million across 5 years, with a median of $35.2 million in 2022.
- Biggest five-year swings in Common Equity: skyrocketed 191.13% in 2021 and later plummeted 194.7% in 2025.
- Tracing IMDX's Common Equity over 5 years: stood at $65.2 million in 2021, then crashed by 47.42% to $34.3 million in 2022, then crashed by 40.31% to $20.5 million in 2023, then plummeted by 159.97% to -$12.3 million in 2024, then tumbled by 156.35% to -$31.5 million in 2025.
- Business Quant data shows Common Equity for IMDX at -$31.5 million in Q4 2025, -$9.2 million in Q3 2025, and $1.1 million in Q2 2025.